Critique of the Two-fold Measure of Prediction Success for Ratios: Application for the Assessment of Drug-drug Interactions Publication Critique of the Two-fold Measure of Prediction Success for Ratios: Application for the Assessment of Drug-drug Interactions Current assessment of drug-drug interaction (DDI) prediction success is based on whether predictions fall within a two-fold range of the observed data. This strategy…CertaraFebruary 1, 2011
Applications of Physiologically-based Pharmacokinetic (PBPK) Modeling and Simulation During Regulatory Review Publication Applications of Physiologically-based Pharmacokinetic (PBPK) Modeling and Simulation During Regulatory Review Physiologically based pharmacokinetic (PBPK) modeling and simulation is a tool that can help predict the…CertaraFebruary 1, 2011
Assessment of Algorithms for Predicting Drug-drug Interactions Via Inhibition Mechanisms: Comparison of Dynamic and Static Models Publication Assessment of Algorithms for Predicting Drug-drug Interactions Via Inhibition Mechanisms: Comparison of Dynamic and Static Models The prediction of drug-drug interactions (DDIs) from in vitro data usually utilizes an average dosing…CertaraJanuary 1, 2011
Modeling Disease Progression in Acute Stroke Using Clinical Assessment Scales Publication Modeling Disease Progression in Acute Stroke Using Clinical Assessment Scales This article demonstrates techniques for describing and predicting disease progression in acute stroke by modeling…CertaraDecember 1, 2010
Development of a Modeling Framework to Simulate Efficacy Endpoints for Motesanib in Thyroid Cancer Patients Publication Development of a Modeling Framework to Simulate Efficacy Endpoints for Motesanib in Thyroid Cancer Patients To develop a modeling framework that simulates clinical endpoints (objective response rate and progression-free survival)…CertaraNovember 1, 2010
Population Pharmacokinetic/Pharmacodynamic Modeling for the Time Course of Tumor Shrinkage by Motesanib in Thyroid Cancer Patients Publication Population Pharmacokinetic/Pharmacodynamic Modeling for the Time Course of Tumor Shrinkage by Motesanib in Thyroid Cancer Patients To develop a population pharmacokinetic/pharmacodynamic model describing the relationship between motesanib exposure and tumor response…CertaraNovember 1, 2010
Determination of a Quantitative Relationship Between Hepatic CYP3A5*1/*3 and CYP3A4 Expression for Use in the Prediction of Metabolic Clearance in Virtual Populations Publication Determination of a Quantitative Relationship Between Hepatic CYP3A5*1/*3 and CYP3A4 Expression for Use in the Prediction of Metabolic Clearance in Virtual Populations The creation of virtual populations allows the estimation of pharmacokinetic parameters, such as metabolic clearance…CertaraNovember 1, 2010
Incorporating Human Dosimetry and Exposure into High-throughput In Vitro Toxicity Screening Publication Incorporating Human Dosimetry and Exposure into High-throughput In Vitro Toxicity Screening Many chemicals in commerce today have undergone limited or no safety testing. To reduce the…CertaraOctober 1, 2010
Mechanistic Toxicokinetic Model for γ-Hydroxybutyric Acid: Inhibition of Active Renal Reabsorption as a Potential Therapeutic Strategy Publication Mechanistic Toxicokinetic Model for γ-Hydroxybutyric Acid: Inhibition of Active Renal Reabsorption as a Potential Therapeutic Strategy γ-Hydroxybutyric acid (GHB), a drug of abuse, exhibits saturable renal clearance and capacity-limited metabolism. The …CertaraSeptember 1, 2010
A Pharmacokinetic/Pharmacodynamic Model for Cardiovascular Safety Assessment of R1551 Publication A Pharmacokinetic/Pharmacodynamic Model for Cardiovascular Safety Assessment of R1551 Pharmacokinetic-pharmacodynamic relationships are crucial in understanding a drug's arrhythmogenic potential. Models assist to quantitatively relate…CertaraAugust 21, 2010